Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2013 · 10-Q
Revenue$2.72M$2.72M−25.2% vs Q3 2012 Net Income-$1.25M-$1.25MN/M vs Q3 2012 EPS Diluted-$0.01-$0.01N/M vs Q3 2012 Gross Profit$750,187−40.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$87,117N/M Free Cash Flowderived-$165,629N/M Margins · derivedGross margin27.6%−6.9 pt vs Q3 2012
Operating margin-45.7%−3.5 pt vs Q3 2012
Net margin-46.0%−3.7 pt vs Q3 2012
ended Sep 28, 2013 · filed Nov 21, 2013 · 54 d after period end